Seviteronel - Emerging Drug Insight and Market Forecast - 2030
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
Seviteronel（INO-464）は、CYP17リアーゼおよびAR (アンドロゲン受容体) の選択的阻害剤であり、前立腺がんや乳がんの治療に利用可能だと見込まれています。また、ARが引き起こす他のがん (卵巣がん・膀胱がん・肝臓がん・肺がんなど) や、性ステロイドの過剰生産が原因の非腫瘍性症候群 (子宮内膜症、多嚢胞性卵巣症候群、先天性副腎過形成、思春期早発症など) の治療への適用も期待されています。
当レポートでは、前立腺がん・乳がん等の治療薬であるSeviteronelの市場構造・動向について分析し、製品の概要 (用法・容量、作用機序など) や関連規制、製品開発・治験の進行状況、主要7ヶ国 (米国、欧州5ヶ国 (ドイツ、フランス、イタリア、スペイン、英国)、日本) の市場規模の動向見通し (2020～2030年)、市場の競争状態・SWOT分析、他の治療薬との競合状態、資本取引の動き、今後の市場成長の可能性などを調査・考察しております。
"Seviteronel- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prostate cancer in 7 Major Markets. A detailed picture of the Seviteronel in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Seviteronel (INO-464) is a selective CYP17 lyase and AR inhibitor and the broad collection of multiple patented chemical classes of related compounds that were invented by scientists at Viamet Pharmaceuticals are wholly owned by Innocrin. Innocrin has identified high priority leads that have high CYP17 lyase potency and selectivity. It is Innocrina€s intent to leverage its organizational expertise to advance one or more of these 2nd-generation leads into clinical development. In addition to their potential use for the treatment of breast cancer and CRPC, inhibitors that target both CYP17 lyase and AR also have potential for the treatment of other cancers driven by the AR including ovarian, bladder, hepatocellular, and lung. Similarly, these inhibitors may also have commercial potential for the treatment of non-oncologic syndromes that are due to excess sex steroid production. These conditions include endometriosis, polycystic ovary syndrome, congenital adrenal hyperplasia, and precocious puberty, among others. Safety and convenience are important attributes of our product candidates.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of Seviteronel in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of Seviteronel covering trial interventions, trial conditions, trial status, start and completion dates.